Aimmune Therapeutics (AIMT): Expecting Success In Palisades Trial - Piper Jaffray

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Aimmune Therapeutics (NASDAQ: AIMT) after the company hosted a call with Dr. Vickery, lead author of the recently published academic DEVIL study of OIT for peanut allergy in very young children.

DEVIL demonstrated high levels of sustained unresponsiveness to peanut even after OIT withdrawal, suggesting clinically meaningful protection and perhaps even a disease modifying effect, combined with “unexpectedly good” tolerability. The analyst believes these encouraging results are supportive of the potential differentiation of OIT (vs subcutaneous & epicutaneous methods) for desensitization and perhaps disease course modification, which Aimmune’s AR101 can bring to the larger peanut allergy market.

The analyst stated "we also sees the DEVIL results as reinforcing his conviction in the design and high probability of success of the PALISADE trial, as well as AR101 study in young children during 2017. In advance of PALISADE enrollment completion expected during 2H16, we continue to see clear advantages of OIT and AR101 versus other approaches to peanut allergy".

No change to the price target of $38.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $14.93 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Itau BBA Reiterates Outperform Rating on Klabin SA (KLBN11:BZ) (KLBAY)
• United Community Banks (UCBI) PT Lowered to $28 at Piper Sandler